Elanco Animal Health Inc

Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elanco Animal Health reports mixed 2022 results, eyes innovation growth

Elanco Animal Health's 2022 performance showed revenue decline but EPS growth, with a focus on innovation and portfolio strength for future growth.
The company aims to address challenges like competitive pressures and interest expenses while leveraging opportunities in product launches and margin improvement.
Financial projections include a net leverage ratio target for 2023, with plans for debt reduction and enhanced cash flow generation in the coming years.
Elanco's strategic focus on OTC parasiticides, innovation, and operational efficiency positions it well for sustained growth and market differentiation.

Elanco Animal Health reports Q1 growth and strategic outlook

Elanco Animal Health's Q1 2023 performance showcased revenue growth, strategic advancements, and improved cash flow generation, supported by successful ERP system integration benefits.
Despite challenges related to free cash flow, inventory discrepancies, and regulatory discussions, the company remains focused on optimizing working capital and enhancing financial metrics.
Opportunities lie in debt repayment, maintaining pricing benefits, upcoming product launches, and returning to growth in the second half of 2023, underpinned by global macro trends.
Elanco's strengths in market positioning, innovation progress, and strategic outlook for 2024 position the company for sustained growth and operational excellence in the animal health sector.

Elanco Animal Health surpasses Q2 targets, eyes global market growth

Elanco Animal Health exceeded Q2 targets, focusing on innovation and market expansion. While facing challenges in certain segments, the company is optimistic about future growth opportunities through differentiated products and global market strengths.

Elanco Animal Health excels in Q3, eyes sustained growth in 2024

Elanco Animal Health delivered a strong Q3 performance, emphasizing innovation and growth in international segments. While facing challenges in U.S. Pet Health and Farm Animal generics, the company is focused on driving sustainable growth through margin expansion and new product launches. Opportunities lie in upcoming blockbuster product launches and pricing strategies for 2024.

Elanco Animal Health reports growth in Q4 2023 earnings

Elanco Animal Health's Q4 2023 performance showed revenue growth driven by innovation and Farm Animal business strength.
Strategic restructuring aims to enhance efficiency and focus on pet health, while challenges include competitive pressures and margin headwinds.
Opportunities lie in continued growth, innovation, debt reduction, and commitment to new product sales targets.
Overall, Elanco remains confident in its position and ability to navigate market challenges.

Elanco Animal Health surpasses Q1 expectations, eyes revenue growth

Elanco Animal Health's Q1 2024 performance exceeded expectations, driven by strong Pet Health and Farm Animal segment growth, alongside improved cash flow and late-stage pipeline progress.
Despite challenges like product manufacturing issues and market queries, Elanco remains focused on innovation, market positioning, and executing its value agenda.
The company is poised for revenue growth, with positive outlooks for late-stage products and opportunities to capitalize on market demand and competitive strategies.
Elanco's strategic approach to product launches, market readiness, and portfolio expansion positions it well for future growth and market leadership.

Elanco Animal Health reports strong Q3 performance and growth outlook

Elanco Animal Health's Q3 performance reflects growth in key segments and products, with a focus on debt reduction and strategic investments.
The company faces challenges in competitive markets and supply chain transitions but is poised for growth through new product launches and market adoption.
Opportunities lie in expanding product reach, driving innovation sales, and navigating pricing trends to achieve mid-single-digit growth in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the fourth quarter and full year 2022, and provided initial guidance both for the first half and full year 2023.

Elanco Animal Health Reports Fourth Quarter and Full Year 2022 Results

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health (NYSE: ELAN) announced today the appointment of Tim Bettington as the company's executive vice president Corporate Strategy and Market Development. He will join Elanco's executive committee on March 20.

Elanco Adds Animal Health Veteran to Executive Committee

GREENFIELD, Ind.--( BUSINESS WIRE )--Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.

Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2022 Financial Results Announcement

GREENFIELD, Ind.--( BUSINESS WIRE )--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023. Jeff Simmons, president and CEO, will represent the company and respond to questions from analysts at 12:45 p.m. ET.

Elanco to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Elanco Animal Health, an Eli Lilly spin-off, is the second-largest pure-play in the industry. Acquisitions to achieve critical mass resulted in a protracted period of restructuring, reorganization and poor financial performance.

Elanco's Tangible Equity Units: Living With The Worst Case

GREENFIELD, Ind.--( BUSINESS WIRE )--Today Elanco Animal Health (NYSE:ELAN) announced the U.S. Food and Drug Administration (FDA) approved Bexacat™ (bexagliflozin tablets), the first orally administered prescription medication to improve glycemic control in cats with diabetes mellitus, expanding Elanco's innovative feline portfolio while addressing an unmet need for this chronic condition in adult cats.

Elanco Announces FDA Approval of Bexacat™ (bexagliflozin tablets) – the First-of-its-Kind Oral Feline Diabetes Treatment Option

GREENFIELD, Ind.--( BUSINESS WIRE )--Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Evercore ISI 5th Annual HealthCONx Conference on Tuesday, November 29, 2022. Jeff Simmons, president and CEO, will participate in a fireside chat at 8:50 a.m., Eastern time.

Elanco to Participate in Evercore ISI 5th Annual HealthCONx Conference

Elanco Animal Health Incorporated (NYSE:ELAN ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Katy Grissom - Head of Investor Relations Jeff Simmons - President & Chief Executive Officer Ellen de Brabander - Executive Vice President of Innovation & Regulatory Affairs Todd Young - Chief Financial Officer Conference Call Participants Mike Ryskin - Bank of America Erin Wright - Morgan Stanley Umer Raffat - Evercore ISI Nathan Rich - Goldman Sachs Balaji Prasad - Barclays Jonathan Block - Stifel Brandon Vazquez - William Blair Michael Parolari - Raymond James Operator Good morning. My name is Rob, and I will be your conference operator today.

Elanco Animal Health Incorporated (ELAN) Q3 2022 Earnings Call Transcript

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 25% and 0.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Elanco Animal Health Incorporated (ELAN) Q3 Earnings and Revenues Top Estimates

Elanco Animal Health Reports Third Quarter 2022 Results

Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Elanco (ELAN)

Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Elanco Animal Health Incorporated (ELAN) Could Beat Earnings Estimates Again

Like humans, animals also need medicine, vaccines, diagnostics, devices, supplements and doctors (veterinarians). The animal health industry has been growing organically at a pace of about 5% to 7%, and related stocks have also enjoyed volume and price increases of about 2%.

Elanco: Under-Earning but Undervalued

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will announce its third quarter 2022 financial results on Tuesday, November 8, 2022. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elan

Elanco Confirms Date and Conference Call for Third Quarter 2022 Financial Results Announcement

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Scott Ferguson, founder and managing partner of Sachem Head Capital Management LP (“Sachem Head”), is stepping down from the Board of Directors in connection with Ferguson and Sachem Head refocusing his time across other Sachem Head Board commitments. As one of the Company's largest shareholders, Sachem Head will continue to engage with and be a resource for the Board and management team. Ferg

Elanco Announces Changes to its Board of Directors

Freshpet

IDEXX Laboratories

Phibro Animal Health

Zoetis

Despite inflationary pressures that are increasing the price of goods across the board, consumers are still pampering their pets when it comes to food.

5 Pet Care Stocks Gurus Love

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022. Jeff Simmons, president and CEO, will participate in a fireside chat at 2:50 p.m., Eastern time. A live audio webcast will be available in the “Events and Presentations” section of Elanco's investor website. A replay will be available for approximately 90 days. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE

Elanco to Participate in Morgan Stanley 20th Annual Global Healthcare Conference

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE:ELAN) today released its 2021 Environmental, Social and Governance (ESG) Report “Changing The World One Animal at a Time” highlighting the company's progress on relevant ESG topics and metrics. The 2021 ESG Report expands on the company's inaugural 2020 ESG Summary, providing updates on the company's sustainability programs, policies and initiatives as well as metrics and targets in several key areas, including workforce

Elanco Releases 2021 Environmental, Social and Governance Report Highlighting Progress on Healthy Purpose™ Goals

Elanco Animal Health Incorporated (NYSE:ELAN ) Q2 2022 Earnings Conference Call August 8, 2022 8:00 AM ET Company Participants Katy Grissom - Head of Investor Relations Jeff Simmons - President & Chief Executive Officer Todd Young - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Chris Schott - JPMorgan Jon Block - Stifel Mike DiFiore - Evercore ISI Nathan Rich - Goldman Sachs Christine Raines - William Blair Operator Hello and thank you for standing by. My name is Regina, and I will be your conference operator today.

Elanco Animal Health Incorporated (ELAN) CEO Jeff Simmons on Q2 2022 Results - Earnings Call Transcript

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 38.46% and 0.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Elanco Animal Health Incorporated (ELAN) Tops Q2 Earnings Estimates

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the second quarter of 2022, provided guidance for the third quarter of 2022, and updated guidance for the full year 2022. “Our relentless efforts to drive operational efficiency from our company-wide productivity agenda allowed us to grow adjusted EBITDA and adjusted EPS despite topline pressures in the quarter,” said Jeff Simmons, Elanco president and chief executive officer.

Elanco Animal Health Reports Second Quarter 2022 Results

Paramount Global

Shares of these two companies are down more than 20% this year, providing a potential opportunity for investors.

Got $5,000? These 2 Beaten-Down Growth Stocks Are Great Buys Right Now

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2022 financial results on Monday, August 8, 2022. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco

Elanco Confirms Date and Conference Call for Second Quarter 2022 Financial Results Announcement

GREENFIELD, Ind.--(BUSINESS WIRE)--Amidst a surge of pet adoptions, a new survey released by Elanco finds many pets are insufficiently protected against common diseases like Lyme and leptospirosis. Once largely isolated to wooded regions, the threat of Lyme and lepto has escalated in urban and suburban areas due to expanding tick populations across the country. Survey respondents admitted to taking their pet's health and wellbeing seriously. At the same time only 61% said their dogs are vaccina

Elanco Survey Finds Many Pets Live Unprotected Against Preventable Diseases

Elanco (NASDAQ: ELAN), an animal health products company, has seen a 17% fall in a month, underperforming the broader S&P500, which is down 9%.

News for Elanco Animal Health Inc Stock (ELAN)